Advagene Biopharma Co., Ltd.

TPEX:6709 株式レポート

時価総額：NT$1.2b

Advagene Biopharma マネジメント

マネジメント 基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Yu-Shen Hsu

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間2.3yrs
CEOの所有権n/a
経営陣の平均在職期間データなし
取締役会の平均在任期間データなし

経営陣の近況

Recent updates

Advagene Biopharma (GTSM:6709) Is In A Strong Position To Grow Its Business

Mar 24
Advagene Biopharma (GTSM:6709) Is In A Strong Position To Grow Its Business

Here's Why We're Not At All Concerned With Advagene Biopharma's (GTSM:6709) Cash Burn Situation

Dec 10
Here's Why We're Not At All Concerned With Advagene Biopharma's (GTSM:6709) Cash Burn Situation

CEO（最高経営責任者

Yu-Shen Hsu

2.3yrs

在職期間

Mr. Yu-Shen Hsu serves as Chairman of Advagene biopharma Co.,Ltd since August 2022 and has been its Acting President, General Manager and Director.